DEF: Seer, Inc. Announces 2025 Annual Stockholder Meeting Amidst Board Changes and Executive Compensation Adjustments

Seer, Inc. has scheduled its 2025 Annual Meeting of Stockholders for July 7, 2025, to elect directors and ratify its independent auditor, while also detailing executive compensation, including a significant stock option repricing in 2024 due to declining stock value.

Summary

• Seer, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on Monday, July 7, 2025, at 1:00 p.m. Pacific Time.
• Key business items include the election of six directors to serve until the 2026 annual meeting and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025.
• David Hallal, a current director, is not standing for re-election, reducing the board from seven to six members.
• The company reported 2024 revenue of $14.2 million and shipped 10 instruments, bringing cumulative shipments to 72 as of December 31, 2024.
• Executive compensation for 2024 included base salaries, annual performance-based cash bonuses (paid at 75% achievement level for corporate objectives), and long-term equity incentives.
• A significant stock option repricing occurred on October 4, 2024, for options with exercise prices greater than $2.00, resetting them to $2.00 per share, due to a substantial portion of employee options being 'underwater'.
• New 2024 equity grants for executives include stock options with market performance conditions requiring the stock price to increase by 300% for the CEO and 200% for other named executive officers from the grant date price of $1.77.
• The company repurchased approximately 6.5 million shares of Class A common stock at an average cost of $1.82 per share during 2024, reducing shares outstanding by approximately 10%.

Sentiment

Score: 4

Explanation: The sentiment is mixed to slightly negative. While the company highlights operational achievements (revenue, instruments, partnerships, share repurchases) and robust corporate governance, the significant stock price decline leading to underwater options and a subsequent repricing, along with negative 'Compensation Actually Paid' figures for prior years, indicates substantial challenges in shareholder value creation and executive incentive alignment.

Positives

• Achieved revenue of $14.2 million for the full year 2024, indicating continued commercial activity.
• Shipped 10 instruments during 2024, increasing cumulative instruments shipped to 72, demonstrating product adoption.
• Launched the Seer Technology Access Center (STAC) in Europe, expanding global reach and service offerings.
• Entered into a co-marketing and sales agreement with Thermo Fisher Scientific, enhancing market access and global reach for proteomics technology.
• Increased cumulative peer-reviewed publications, preprints, and reviews to 32 in 2024 from 8 in 2023, indicating scientific progress and validation.
• Repurchased approximately 6.5 million shares of Class A common stock at an average cost of $1.82 per share, reducing shares outstanding by approximately 10%, which can be accretive to shareholder value.
• Maintains a strong corporate governance framework with a majority of independent directors and specialized committees (Audit, Talent & Compensation, Corporate Governance & Nominating, Science & Technology).
• Implemented a Compensation Recovery Policy (Clawback Policy) in compliance with SEC rules, enhancing accountability.
• Prohibits executives from engaging in hedging or pledging transactions with company common stock, aligning executive interests with long-term shareholder value.
• Offers competitive pay and benefits, including equity ownership opportunities for all full-time employees, and invests in employee development and training, contributing to talent retention and a positive workplace culture (certified 'Great Place to Work' for five consecutive years).

Negatives

• The 'Compensation Actually Paid' to the Principal Executive Officer (PEO) was negative in 2023 (-$136,662) and significantly negative in 2022 (-$15,544,219), indicating a substantial decline in the fair value of equity awards.
• The average 'Compensation Actually Paid' to Non-PEO Named Executive Officers (NEOs) was also negative in 2023 (-$320,892) and significantly negative in 2022 (-$11,582,853), reflecting similar equity value declines.
• The company's stock price significantly decreased, leading to a substantial portion of employee stock options becoming 'underwater', necessitating a repricing of options on October 4, 2024.
• Net Income was negative for all three fiscal years presented: -$86,599 thousand in 2024, -$86,277 thousand in 2023, and -$92,966 thousand in 2022, indicating ongoing losses.
• David Hallal, a director since 2018 and former Lead Independent Director, is not standing for re-election, leading to a reduction in board size and a change in leadership composition.

Risks

• The company faces fierce competition for executive officers and employees with specialized skills and experience in the biotechnology industry, particularly in the San Francisco Bay Area, which could impact talent retention.
• The significant decrease in the company's common stock price has rendered a substantial portion of outstanding stock options 'underwater', potentially reducing their effectiveness as incentives for motivation and retention.
• The reliance on stock options with high market performance conditions (200-300% increase from grant date price) means that a substantial portion of executive compensation is at risk and dependent on significant stock price appreciation, which may not materialize.
• The company's Compensation Recovery Policy allows for the clawback of certain compensation in the event of an accounting restatement, indicating a risk of financial reporting errors or misconduct.
• The company has consistently reported negative net income, which poses a risk to long-term financial sustainability if profitability is not achieved.

Future Outlook

The document does not provide specific forward-looking financial guidance or estimates. However, the executive compensation program is designed to incentivize long-term value creation, with equity awards tied to future stock price growth (e.g., 200-300% increase hurdles). The company's strategic initiatives, such as the European Technology Access Center and the Thermo Fisher Scientific co-marketing agreement, are aimed at future growth and expanded global reach.

Management Comments

• Omid Farokhzad, M.D., Chief Executive Officer and Chair of the Board of Directors, expressed pleasure in inviting stockholders to the 2025 Annual Meeting and thanked them for their continued support and interest in Seer.
• The Board believes that holding the annual meeting in a virtual format provides the opportunity for participation by a broader group of stockholders, while reducing costs and providing for health and safety.
• The Board intends for the virtual meeting format to provide stockholders a level of transparency as close as possible to the traditional in-person meeting format, by allowing advance and real-time questions, answering questions without discrimination, and offering separate engagement opportunities.

Industry Context

The document highlights a 'fierce competition' and 'war for talent' in the biotechnology industry, particularly in the San Francisco Bay Area, which influences the company's executive compensation strategies, including the use of retention grants. The co-marketing and sales agreement with Thermo Fisher Scientific indicates a trend towards strategic partnerships to enhance market access and expand global reach within the life sciences and proteomics sector.

Comparison to Industry Standards

• The company uses a peer group of pharmaceutical, biotechnology, life science, and healthcare equipment/services companies (with revenues generally less than $200 million, market capitalization $50 million to $650 million, and 50-500 employees) to benchmark executive compensation.
• Target cash compensation (salary and bonus) is generally set with a focus on the median of the compensation peer group.
• Equity compensation for executives is balanced between the dollar value (closer to the 25th percentile of the peer group) and the equity compensation as a percentage of company ownership (closer to the 75th percentile), aiming to align executive interests with stockholders and encourage retention.
• The document does not provide specific comparisons of the company's financial performance (e.g., revenue growth, net income, or profitability) against industry standards or specific competitors within its peer group.

Management Changes

Corporate Governance

Related Party Transactions

• The company is party to an amended and restated investors rights agreement (IRA) with certain holders of its capital stock, including entities affiliated with Omid Farokhzad, M.D., Robert Langer, Sc.D., and Terrance McGuire, which provides demand and piggyback registration rights.
• The company has entered into indemnification agreements with its directors and executive officers, requiring indemnification to the fullest extent permitted by Delaware law.

Stakeholder Impact

• **Shareholders**: Will vote on director elections and auditor ratification. The stock option repricing and negative 'Compensation Actually Paid' figures indicate past poor shareholder returns, but the share repurchase program and new performance-based equity awards aim to align interests and create future value.
• **Employees**: Executive compensation adjustments, including the option repricing and retention grants, are intended to motivate and retain key talent amidst fierce industry competition. Employees also benefit from competitive pay, comprehensive healthcare, and equity ownership opportunities.
• **Customers**: The launch of the Seer Technology Access Center in Europe and the co-marketing agreement with Thermo Fisher Scientific aim to enhance access to the company's technology and services, potentially benefiting customers through broader availability and support.
• **Management**: Executive compensation is directly tied to corporate goals and long-term equity performance, incentivizing achievement of strategic priorities. Severance and change-in-control benefits provide security for key executives.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders virtually on July 7, 2025.
• Elect six directors to serve until the 2026 annual meeting of stockholders.
• Ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025.
• File a current report on Form 8-K within four business days after the Annual Meeting to disclose preliminary or final voting results.
• Prepare for the 2026 Annual Meeting of Stockholders, including considering stockholder proposals and director nominations by specified deadlines (January 28, 2026, for proxy inclusion; March 14 April 13, 2026, for advance notice; May 8, 2026, for universal proxy rule notice).

Key Dates

Recommendation

Keywords

Seer, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Stock Options, Restricted Stock Units, Board of Directors, Auditor Ratification, Shareholder Meeting, Biotechnology, Life Sciences, Proteomics, Option Repricing, Share Repurchase